Search News:

LEXINGTON, Mass.--(BUSINESS WIRE)--Predictive
Biosciences, an innovative developer of molecular diagnostic tests,
today announced the appointment of Pierre
Cassigneul as the company’s new chief executive officer. Mr.
Cassigneul is a seasoned executive with more than 25 years of commercial
experience in the healthcare and molecular diagnostic industries. He
brings significant international and product commercialization
experience to Predictive Biosciences, having held top management
positions at several leading global diagnostics companies. Mr.
Cassigneul replaces Marc
Schneebaum, who will return to his original role as chief operating
officer.

“I am very excited to be joining the company at this important
inflection point in its commercial growth and look forward to working
with such a remarkable team, both in vision and scientific excellence”

“I am very excited to be joining the company at this important
inflection point in its commercial growth and look forward to working
with such a remarkable team, both in vision and scientific excellence,”
said Pierre Cassigneul, chief executive officer. “Predictive’s novel
approach and compelling clinical data from several multi-center clinical
trials have resulted in significant adoption of the CertNDx™
Bladder Cancer Assay in the urology community. I believe the CertNDx
tests have the potential to greatly improve the diagnosis and management
of bladder cancer. We will be evaluating opportunities for in vitro
diagnostic kit development and expansion into the primary care market.
In addition to bladder cancer, there is also a need for improved
management of patients with prostate cancer. This novel approach of
stratifying patients is being utilized to develop CertNDx tests for
prostate cancer.”

Mr. Cassigneul previously served as vice chairman of the board and
president and chief executive officer of XDx
Inc., a molecular diagnostics company focused on non-invasive gene
expression testing. Under his leadership, XDx received Food and Drug
Administration (FDA) clearance for and launched the AlloMap®
Gene Expression Test for use in transplant management, representing the
first U.S. molecular diagnostics company to obtain FDA approval of an in
vitro diagnostic multivariate index assay (IVDMIA). Additionally, he has
held top management positions at Becton Dickinson, Bayer Diagnostics,
Ortho Diagnostic Systems (Johnson & Johnson) and Abbott Laboratories in
the diagnostics division. He also served on the board of the
Personalized Medicine Coalition.

“We thank Marc for a tremendous year of achievements during his
leadership as CEO and for his continued support as COO,” said Michael
A. Greeley, chairman of Predictive Biosciences’ board of directors
and general partner at Flybridge Capital Partners. “We look forward to
working closely with Pierre as he builds on the company’s success to
date and defines the future strategic direction for Predictive. We
believe he has the leadership and commercial track record that will be
critical to the next phase of the company’s growth as we focus on
maximizing the potential of the CertNDx product line.”

About Predictive Biosciences

Predictive Biosciences develops novel molecular diagnostic cancer assays
and provides molecular pathology services for urology-based practices.
Leveraging a portfolio of patented biomarkers and clinical approaches,
the company has built a unique portfolio of assays for cancer
management, first targeted at bladder and prostate cancer. The company
is backed by leading investors, including Flybridge Capital Partners,
Highland Capital Partners, Kaiser Permanente Ventures, New Enterprises
Associates, Inc. (NEA) and ProQuest Investments. For additional
information, please visit www.predictivebiosci.com.